Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Common Equity (2016 - 2025)

Wave Life Sciences' Common Equity history spans 11 years, with the latest figure at $518.4 million for Q4 2025.

  • For Q4 2025, Common Equity rose 147.41% year-over-year to $518.4 million; the TTM value through Dec 2025 reached $518.4 million, up 147.41%, while the annual FY2025 figure was $518.4 million, 147.41% up from the prior year.
  • Common Equity reached $518.4 million in Q4 2025 per WVE's latest filing, up from $124.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $518.4 million in Q4 2025 to a low of -$51.7 million in Q2 2023.
  • Average Common Equity over 5 years is $67.9 million, with a median of $30.4 million recorded in 2021.
  • Peak YoY movement for Common Equity: crashed 65398.11% in 2023, then skyrocketed 4105.35% in 2025.
  • A 5-year view of Common Equity shows it stood at $32.5 million in 2021, then crashed by 238.75% to -$45.1 million in 2022, then soared by 187.89% to $39.6 million in 2023, then skyrocketed by 428.68% to $209.5 million in 2024, then soared by 147.41% to $518.4 million in 2025.
  • Per Business Quant, the three most recent readings for WVE's Common Equity are $518.4 million (Q4 2025), $124.5 million (Q3 2025), and $139.3 million (Q2 2025).